SACLAC

Overview

SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a K i of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Ceramidase | Products > Signaling Pathways > Bcl-2 Family | Products > Signaling Pathways > LPL Receptor | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-158783
• CAS No.: 2248703-42-4
• Molecular Formula: C20H40ClNO3
• Molecular Weight: 377.99
• Purity: 99.70%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1 mg/mL (2.65 mM); Clear solution
• Availability: In-stock

Source

Original product source